Intriguingly, Chen and colleagues reported that high levels of CD44, another stem cell marker associated with an invasive phenotype similar to CD90, are also linked to gemcitabine resistance in pancreatic cancer cells and preclinical models [35]. This evidence concerns the gene CD44 and familial pancreatic carcinoma.